Impact of Oxycodone HCl Extended-release Formulary Restrictions on Extended-release Opioid Market Share, Healthcare Resource Utilization and Costs in Commercial and Medicare Plans
**Background:** Previous research demonstrated that utilization management (UM) such as prior authorization (PA) or non-formulary (NF) restrictions may reduce pharmacy costs when designed and applied appropriately to certain drug classes. However, such access barriers may also have unintended conseq...
Saved in:
Main Authors: | Rolin L. Wade, Chi-Chang Chen, Ajita P. De, Jaren C. Howard |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2017-07-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/9800 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Subcutaneous Extended-Release Buprenorphine Use in Pregnancy
by: Craig V. Towers, et al.
Published: (2020-01-01) -
Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease
by: Wolfram Eisenreich, et al.
Published: (2010-01-01) -
New restricted and extended soft set operations: restricted gamma and extended gamma operations
by: Aslıhan Sezgin, et al.
Published: (2024-12-01) -
Assessing the Subjective and Physiological Effects of Intranasally Administered Crushed Extended-Release Morphine Formulations with and without a Sequestered Naltrexone Core in Recreational Opioid Users
by: Beatrice Setnik, et al.
Published: (2013-01-01) -
Case report: Local anesthesia with lidocaine infiltration for extended-release buprenorphine therapy
by: Pouya Azar, et al.
Published: (2025-01-01)